Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias with Nutlin

ABSTRACT: RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias with Nutlin

PROVIDER: PRJNA1103844 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28784500_1.fastq.gz	Fastqsanger.gz
	SRR28784500_2.fastq.gz	Fastqsanger.gz
	SRR28784495_1.fastq.gz	Fastqsanger.gz
	SRR28784495_2.fastq.gz	Fastqsanger.gz
	SRR28784496_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias with Nutlin

Project description:Transcriptional effects of Nutlin treatment in murine MA9 leukemia after loss of Gata2.

2025-04-30 | GSE264720 | GEO

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias.

Project description:RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias.

| PRJNA1104155 | ENA

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias.

Project description:Transcriptional effects of Gata2 deletion in murine MA9 leukemia.

2025-04-30 | GSE265756 | GEO

Gata2 promotes drug resistance in Acute Myeloid Leukemia (AML)

Project description:In this study, we generated mouse models of MLL-AF9-driven AML (MA9) harboring conditional alleles for Gata2 gene to precisely investigate the role of Gata2 in drug resistance and progression of MLL-rearranged (MLL-r) AML. Our findings revealed a novel mechanism for Gata2 in blunting p53 mediated apoptosis via transcriptional repression of Rassf4, a regulator of Mdm2 protein stability.

2025-05-01 | GSE266623 | GEO

Gata2 promotes drug resistance in Acute Myeloid Leukemia (AML) [ChIP-Seq]

2025-04-30 | GSE264719 | GEO

Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets [RNA-Seq_normal]

Project description:Next generation DNA sequencing of acute myeloid leukemia (AML) patient samples has revealed novel recurrent mutations while at the same time highlighting the genetic heterogeneity of the disease. These observations suggest that an extraordinarily large number of combinations of mutations can contribute to leukemogenesis. In order to address the question of the contribution of patient genetic background to AML we have developed a model system to generate multiple human leukemias in a single donor’s genetic background. Stepwise RNA-seq data from this model shows that in the context of AML driven by the MLL-AF9 (MA9) oncogene, the genetic background of the donor does not have a detectable effect. Comparison of these model leukemias from multiple single donors to AML patient samples containing MA9 translocations revealed conserved gene expression patterns not previously highlighted in this genetic sub-type. We further demonstrate that the expression of one of these genes, RET, is essential both in vivo and in vitro growth of MA9 AMLs .

2017-05-02 | GSE71689 | GEO

Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets [RNA-Seq_AML]

2017-05-02 | GSE71686 | GEO

Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets [RNA-Seq_normal]

Project description:Next generation DNA sequencing of acute myeloid leukemia (AML) patient samples has revealed novel recurrent mutations while at the same time highlighting the genetic heterogeneity of the disease. These observations suggest that an extraordinarily large number of combinations of mutations can contribute to leukemogenesis. In order to address the question of the contribution of patient genetic background to AML we have developed a model system to generate multiple human leukemias in a single donorâs genetic background. Stepwise RNA-seq data from this model shows that in the context of AML driven by the MLL-AF9 (MA9) oncogene, the genetic background of the donor does not have a detectable effect. Comparison of these model leukemias from multiple single donors to AML patient samples containing MA9 translocations revealed conserved gene expression patterns not previously highlighted in this genetic sub-type. We further demonstrate that the expression of one of these genes, RET, is essential both in vivo and in vitro growth of MA9 AMLs . Transcriptome of normal cells (CD34+) from different donors

2017-05-02 | E-GEOD-71689 | biostudies-arrayexpress

Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets [RNA-Seq_AML]

Project description:Next generation DNA sequencing of acute myeloid leukemia (AML) patient samples has revealed novel recurrent mutations while at the same time highlighting the genetic heterogeneity of the disease. These observations suggest that an extraordinarily large number of combinations of mutations can contribute to leukemogenesis. In order to address the question of the contribution of patient genetic background to AML we have developed a model system to generate multiple human leukemias in a single donorâs genetic background. Stepwise RNA-seq data from this model shows that in the context of AML driven by the MLL-AF9 (MA9) oncogene, the genetic background of the donor does not have a detectable effect. Comparison of these model leukemias from multiple single donors to AML patient samples containing MA9 translocations revealed conserved gene expression patterns not previously highlighted in this genetic sub-type. We further demonstrate that the expression of one of these genes, RET, is essential both in vivo and in vitro growth of MA9 AMLs . Transcriptome of several AML cell lines

2017-05-02 | E-GEOD-71686 | biostudies-arrayexpress

Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets (Leukemia Cell Bank)

2017-05-02 | GSE72061 | GEO